Corcept Therapeutics
CORT
239 hedge funds and large institutions have $2.24B invested in Corcept Therapeutics in 2022 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 91 increasing their positions, 78 reducing their positions, and 19 closing their positions.
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
17% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 78
11% more capital invested
Capital invested by funds: $2.02B → $2.24B (+$218M)
6% more funds holding
Funds holding: 225 → 239 (+14)
2.6% more ownership
Funds ownership: 79.03% → 81.63% (+2.6%)
8% less call options, than puts
Call options by funds: $8.13M | Put options by funds: $8.8M
Top Buyers
| 1 |
PA
Parallel Advisors
San Francisco,
California
|
+$28.1M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$21.4M |
| 3 |
Man Group
London,
United Kingdom
|
+$20M |
| 4 |
BlackRock
New York
|
+$19.3M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$18.8M |
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$17M |
| 2 |
Millennium Management
New York
|
-$14.1M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$8.02M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$5.71M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$4.36M |
CORT Hedge Fund Activity: Q3 2022 in Review
239 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2022, worth a combined $2.24B — up 11% from $2.02B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CORT positions and 19 closed out — a net gain of 16 holders — while 91 added to existing stakes and 78 trimmed.
The largest buyer was Parallel Advisors, adding an estimated $28.1M. The largest seller was Renaissance Technologies, cutting an estimated $17M.
- 239 institutional investors held Corcept Therapeutics (CORT) as of Q3 2022, up from 225 in Q2 2022.
- Funds reported $2.24B of Corcept Therapeutics stock for Q3 2022, up 11% quarter-over-quarter.
- 35 funds opened new Corcept Therapeutics positions in Q3 2022 and 19 closed out, a net change of +16 holders.
- The largest Corcept Therapeutics buyer in Q3 2022 was Parallel Advisors, an estimated $28.1M added.
- The largest Corcept Therapeutics seller in Q3 2022 was Renaissance Technologies, an estimated $17M sold.
Based on aggregated 13F filings for Q3 2022.